Pharmacokinetics and dosage of fluconazole in continuous hemofiltration (CAVH, CVVH) and hemodialysis (CAVHD, CVVHD) |
| |
Authors: | Pittrow L Penk A |
| |
Affiliation: | Pfizer GmbH, Abteilung Medizin, Karlsruhe, Deutschland. |
| |
Abstract: | Continuous haemofiltration (CAVH, CVVH) and haemodialysis (CAVHD, CVVHD) are increasingly used in patients with acute renal failure (ARF). The elimination rates of fluconazole vary considerably among the different procedures. In CVVHD, the elimination rate is, depending on the combined dialysate/ultrafiltrate flow rate, the most marked compared to CVVH and intermittent dialysis with a fluconazole clearance exceeding the values of healthy persons in CVVHD 2 L/h. To achieve therapeutic plasma levels during continuous renal replacement therapy, the same loading dose as in patients without renal failure should be applied, followed by the adjusted maintenance dose for anuric patients multiplied by a factor taking the extracorporeal elimination of the absorbed dose into account (CAVH, CVVH: x 2.2, ultrafiltrate flow 0.5 L/h; CAVHD, CVVHD: x 3.8, combined dialysate/ultrafiltrate flow 1.5 L/h). Despite the broad therapeutic margin of fluconazole, drug monitoring is recommended with respect to the very limited number of investigations with relatively low dosages up to 200 mg/day and--which is of paramount importance--to achieve therapeutic drug levels in vital indications. |
| |
Keywords: | Fluconazol Pharmakokinetik Dosierung Hämofiltration Hämodialyse CAVH CVVH CAVHD CVVHD Nierenversagen Plasmaspiegel Drug Monitoring Candidämie Fluconazole pharmacokinetics dosage haemofiltration Haemodialysis CAVH CVVH CAVHD CVVHD renal failure plasma concentration drug monitoring candidaemia |
本文献已被 PubMed 等数据库收录! |
|